BriaCell Acquires Sapientia Pharmaceuticals

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) entered into a definitive share exchange agreement with its wholly-owned subsidiary, BriaCell Therapeutics, Sapientia Pharmaceuticals and all the shareholders of Sapientia.
As quoted in the press release:

Pursuant to the terms of the Share Exchange Agreement, BriaCell USA has agreed to acquire from the Sapientia Shareholders all of the issued and outstanding shares in the capital of Sapientia as at the date hereof in consideration to the Sapientia Shareholders, pro rata, of an aggregate of 2,500,000 common shares in the capital of BriaCell (the “Transaction“). As part of the Transaction, BriaCell acquired all rights, including composition of matter patents, and preclinical study data to a novel therapeutic technology platform, known as protein kinase C delta (PKCδ) inhibitors, which represents a unique, highly-targeted approach to treat cancer and to boost the immune system.

Click here to read the full press release.

Source: www.marketwired.com